Spyre Therapeutics Inc. announced that it will present scientific posters at the 21st Congress of the European Crohn's and Colitis Organisation (ECCO) on follow-up interim Phase 1 results for SPY003, a half-life extended anti-IL-23 monoclonal antibody being developed for inflammatory bowel disease. The company said the interim data include follow-up out to 20 weeks and will be presented in a poster suggesting potential for quarterly or twice-yearly maintenance dosing. Spyre also said it will present details of SKYLINE-UC, a platform trial in ulcerative colitis evaluating three long-acting antibodies as single agents and in combinations, along with preclinical mouse colitis data on combined anti-TL1A and anti-IL-23 therapy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyre Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9656433-en) on February 18, 2026, and is solely responsible for the information contained therein.